| Literature DB >> 32000727 |
Annika Lundkvist Josenby1,2, Tomasz Czuba3, Ann I Alriksson-Schmidt4.
Abstract
BACKGROUND: In the Swedish population-based follow-up program and national quality registry for individuals with cerebral palsy (CPUP), physiotherapy (PT) and occupational therapy (OT) treatments are regularly recorded along with functional status. By Swedish law, all citizens irrespective of personal characteristics or socioeconomic status, have the right to receive healthcare and medical treatments as applicable. Previous research has shown gender differences in treatments and interventions received by children with cerebral palsy (CP). The purpose of this study was to examine differences in treatments and interventions by gender and place of birth in children and adolescents participating in CPUP.Entities:
Keywords: Cerebral palsy; Gender; Occupational therapy; Physiotherapy; Sex; Treatment
Mesh:
Year: 2020 PMID: 32000727 PMCID: PMC6993351 DOI: 10.1186/s12887-020-1926-4
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Characteristics and distributions of physiotherapy related interventions in children with cerebral palsy
| Variable, | Boys, | Girls, | Total, |
|---|---|---|---|
| Physiotherapy assessment form, | |||
| Place of birth, | |||
| Nordic country | 1305 (85.4) | 924 (83.5) | 2229 (84.6) |
| Outside of the Nordic countries | 223 (14.6) | 183 (16.5) | 406 (15.4) |
| Gross Motor Function Classification System levels, n = 2635 | |||
| I | 699 (45.7) | 508 (45.9) | 1207 (45.8) |
| II | 263 (17.2) | 190 (17.2) | 453 (17.2) |
| III | 156 (10.2) | 113 (10.2) | 269 (10.2) |
| IV | 223 (14.6) | 150 (13.6) | 373 (14.2) |
| V | 187 (12.2) | 146 (13.2) | 333 (12.6) |
| Spasticity score, mean (SD), range, | 18.75 (16.29), 0–95.83 | 17.68 (15.15), 0–87.5 | 18.30 (15.83), 0–95.83 |
| Received botulinum toxin A in the lower extremities since the last CPUP*assessment, | |||
| Yes | 304 (21.0) | 187 (17.8) | 491 (19.6) |
| Intrathecal baclofen (pump), | |||
| Yes | 38 (2.8) | 15 (1.5) | 53 (2.3) |
| Spasticity reducing medication (oral), | |||
| Yes | 103 (7.2) | 74 (7.1) | 177 (7.2) |
| Selective dorsal rhizotomy, | |||
| Yes | 45 (4.0) | 15 (1.9) | 60 (3.1) |
| Received physiotherapy treatment since last CPUP* assessment | |||
| Yes | 1076 (72.5) | 785 (73.0) | 1861 (72.7) |
| Use of spinal brace, | |||
| Yes | 124 (8.4) | 100 (9.4) | 224 (8.8) |
| Assistive device to facilitate standing, | |||
| Yes | 421 (30.1) | 308 (30.1) | 729 (30.1) |
* National registry and cerebral palsy follow-up program (CPUP)
Characteristics and distributions of occupational therapy related interventions in children with cerebral palsy
| Variable, | Boys, | Girls, | Total, |
|---|---|---|---|
| Occupational therapy assessment form, | |||
| Place of birth, n = 3480 | |||
| Nordic country | 1701 (84.5) | 1214 (82.8) | 2915 (83.8) |
| Outside of the Nordic countries | 313 (15.5) | 252 (17.2) | 565 (16.2) |
| Manual Ability Classification System levels, | |||
| I | 608 (30.8) | 458 (32.1) | 1066 (31.4) |
| II | 503 (25.5) | 335 (23.5) | 838 (24.7) |
| III | 304 (15.4) | 219 (15.4) | 523 (15.4) |
| IV | 234 (11.9) | 168 (11.8) | 402 (11.8) |
| V | 323 (16.4) | 245 (17.2) | 568 (16.7) |
| Received botulinum toxin A in the upper extremities since the last CPUP* assessment, n = 3480 | |||
| Yes | 164 (8.1) | 108 (7.4) | 272 (7.8) |
| Orthoses, upper extremities, n = 3480 | |||
| Yes | 330 (16.4) | 254 (17.3) | 584 (16.8) |
| Received occupational therapy treatment since last CPUP* assessment, | |||
| Yes | 670 (36.7) | 453 (34.2) | 1123 (35.7) |
* National registry and Cerebral Palsy follow-up program (CPUP)
Exponentiated coefficients; 95% confidence intervals in brackets of the physiotherapy related treatment modalities
| Outcome variables (yes/no) | |||||||
|---|---|---|---|---|---|---|---|
| Independent variables (reference group) | Use of spinal brace | Received BTX- A since last assessment | Has ITB treatment † | Oral spasticity reducing medication | Undergone SDR surgery | Assistive device for standing | Physiotherapy treatment since last assessment |
| Gender (female) | 1.54* | 0.81 | 0.49 | 0.96 | 0.49* | 1.13 | 1.16 |
| [1.07,2.22] | [0.64,1.02] | [0.22,1.08] | [0.65,1.43] | [0.25,0.94] | [0.80,1.60] | [0.93,1.43] | |
| Place of birth (outside of the Nordic countries) | 1.49 | 0.70 | 0.27* | 0.78 | 0.56 | 0.66 | 0.94 |
| [0.87,2.55] | [0.47,1.05] | [0.074,0.98] | [0.43,1.43] | [0.19,1.71] | [0.38,1.15] | [0.64,1.37] | |
| Gender X place of birth | 0.20*** | 1.48 | 0.85 | 0.77 | 1.08 | 0.66 | 0.64 |
| [0.079,0.53] | [0.81,2.70] | [0.068,10.6] | [0.29,2.02] | [0.16,7.20] | [0.30,1.50] | [0.37,1.11] | |
| Age | 1.05* | 0.98 | 1.28*** | 1.05* | 1.04 | 0.10 | 0.90*** |
| [1.01,1.09] | [0.96,1.00] | [1.17,1.39] | [1.01,1.09] | [0.98,1.11] | [0.96,1.03] | [0.88,0.93] | |
| GMFCS (GMFCS I) | |||||||
| II | 2.77 | 1.17 | 3.57** | 2.75* | 15.92*** | 2.31*** | |
| [0.69,11.1] | [0.86,1.58] | [1.46,8.76] | [1.12,6.76] | [5.48,46.2] | [1.77,3.01] | ||
| III | 9.38*** | 1.40 | 4.36** | 23.23*** | 136.2*** | 4.40*** | |
| [2.78,31.68] | [0.99,2.00] | [1.72,11.07] | [11.0,49.05] | [49.05,378.4] | [2.92,6.61] | ||
| IV | 76.56*** | 1.353 | 1 | 13.10*** | 4.80** | 1001.0*** | 8.22*** |
| [27.19,215.5] | [0.97,1.90] | [1] | [5.86,29.32] | [1.85,12.50] | [355.72816.9] | [5.11,13.24] | |
| V | 222.6*** | 1.030 | 6.53*** | 37.29*** | 0.76 | 1730.4*** | 8.35*** |
| [79.16,625.7] | [0.71,1.50] | [3.11,13.68] | [16.93,82.14] | [0.10,6.02] | [594.75035.1] | [4.90,14.24] | |
| Spasticity score | 1.00 | 1.03*** | 1.00 | 1.03*** | 0.95*** | 1.02*** | 1.02*** |
| [0.99,1.01] | [1.02,1.04] | [0.98,1.02] | [1.02,1.04] | [0.93,0.97] | [1.01,1.03] | [1.01,1.03] | |
Relationship, presented as odds ratio with 95% confidence intervals in brackets, of the physiotherapy reported outcome variables and gender, adjusted for place of birth, age, Gross Motor Function Classification System (GMFCS) levels and spasticity score. BTX-A- Botulinum Toxin- A, ITB- Intrathecal Baclofen, SDR- Selective Dorsal Rhizotomy.
† For intrathecal baclofen, only GMFCS IV and V were analyzed with IV as the reference.
.* p < 0.05, ** p < 0.01, *** p < 0.001
Exponentiated coefficients; 95% confidence intervals in brackets of the occupational therapy related treatment modalities
| Outcome variables (yes/no) | |||
|---|---|---|---|
| Independent variables (reference group) | Orthoses in the upper extremities | BTX- A in upper extremities | Occupational therapy interventions |
| Place of birth (outside of the Nordic countries) | 0.86 | 0.74 | 0.79 |
| [0.62,1.20] | [0.46,1.17] | [0.59,1.04] | |
| Gender (Female) | 1.11 | 0.90 | 0.85 |
| [0.90,1.37] | [0.68,1.20] | [0.71,1.01] | |
| place of birth X gender | 0.97 | 1.18 | 1.36 |
| [0.59,1.61] | [0.59,2.39] | [0.89,2.08] | |
| Age | 1.04*** | 1.02 | 0.94*** |
| [1.02,1.06] | [0.99,1.05] | [0.92,0.96] | |
| Manual Ability Classification System (MACS I) | |||
| II | 9.36*** | 11.92*** | 2.92*** |
| [6.10,14.38] | [6.09,23.34] | [2.32,3.68] | |
| III | 18.41*** | 23.86*** | 4.29*** |
| [11.44,29.65] | [11.70,48.63] | [3.23,5.70] | |
| IV | 31.10*** | 25.52*** | 4.073*** |
| [18.10,53.42] | [11.57,56.31] | [2.86,5.80] | |
| V | 38.95*** | 25.00*** | 5.591*** |
| [21.44,70.78] | [10.53,59.36] | [3.63,8.62] | |
| Gross Motor Function Classification System (GMFCS I) | |||
| II | 0.50*** | 0.56** | 0.90 |
| [0.36,0.69] | [0.37,0.86] | [0.70,1.15] | |
| III | 0.19*** | 0.16*** | 1.10 |
| [0.12,0.31] | [0.079,0.34] | [0.82,1.48] | |
| IV | 0.35*** | 0.54* | 1.41* |
| [0.24,0.52] | [0.33,0.87] | [1.03,1.93] | |
| V | 0.53** | 0.60 | 1.35 |
| [0.33,0.86] | [0.32,1.11] | [0.89,2.05] | |
| Observations | 3397 | 3397 | 3095 |
Relationship, presented as odds ratios with 95% confidence intervals in brackets, of the occupational therapist reported outcome variables and gender, adjusted for place of birth, age, Manual Ability Classification System (MACS) and Gross Motor Function Classification System (GMFCS). BTX-A- Botulinum toxin- A. * p < 0.05, ** p < 0.01, *** p < 0.001